噻托溴铵联合布地奈德吸入治疗哮喘-慢阻肺重叠综合征患者疗效分析

Therapeutic effect of tiotropium combined with budesonide in the treatment of asthma-slow lung obstruction syndrome

目的:观察分析噻托溴铵联合布地奈德吸入治疗哮喘-慢阻肺重叠综合征患者疗效。方法:选取我院2017年5月~2018年5月收治的62例哮喘-慢阻肺重叠综合征(ACOS)患者为本次研究对象,按照临床用药不同将所有患者分为对照组(31例:布地奈德吸入治疗)与实验组(31例:噻托溴铵联合布地奈德吸入治疗),比较两组患者预后。结果:实验组患者治疗72h后一秒用力呼气量(FEV1)、肺活量(VC)与吸气分数(IC/TLC)等相关肺功能指征得分均明显优于对照组,P<0.05。实验组患者治疗后不良反应发生率(9.67%)明显低于对照组(29.00%),P<0.O5。结论:ACOS患者给予噻托溴铵联合布地奈德吸入治疗效果明显优于单纯布地奈德吸入治疗。

Objective:To observe and analyze the efficacy of tiotropium bromide combined with budesonide inhalation in the treatment of asthma-COPD syndrome.Methods:62 patients with asthma-chronic obstructive pulmonary overlap syndrome(ACOS)were treated in our hospital from May 2017 to May 2018.All patients were divided into control group and experimental group according to different clinical medication.31 patients in control group were treated with budesonide inhalation only,and 31 patients in experimental group were treated with tiotropium bromide combined with budesonide.Inhalation of Desonide was used to compare the prognosis of the two groups.Results:The scores of FEV1,VC,IC / TLC and other related pulmonary function indicators in the experimental group were significantly better than those in the control group 72 hours after treatment(P < 0.05).The incidence of adverse reactions in the experimental group(9.67%)was significantly lower than that in the control group (29.00%),P < 0.O5.Conclusion:The effect of inhalation of tiotropium bromide combined with budesonide in ACOS patients is better than that of inhalation of budesonide alone.